Welcome to our pre-clinical evaluation platform for cancer vaccines. Currently, there is a significant research gap in the pre-clinical evaluation of cancer vaccines. Traditional syngeneic models are limited in their application due to the significant differences between mouse and human immune systems. While the CD34+ HSC humanized immune system model has undergone humanization, the immune system cells it constructs are poorly and unstably rebuilt. To better simulate and evaluate the effects of cancer vaccines, we offer a series of highly specialized models that successfully address these issues.
Platform Features and Applications:
• syngeneic-OncVax Cancer Vaccine Model:
We employ immunocompetent animals for tumor vaccine research, utilizing their natural immune systems. Our team possesses extensive experience in animal handling, and the experiments culminate in various detection platforms at the endpoints.
• iHuPBMC-OncVax Cancer Vaccine Model: 
This model comprehensively constructs lymphocytes and myeloid cells, ensuring effective antigen presentation in the body, providing a realistic and effective evaluation environment for cancer vaccines.
• Humanized MHC Mouse Model:
By replacing the MHC molecules of immunocompetent mice with human MHC molecules, we ensure that antigen presentation in mice closely resembles that in humans, thus providing a powerful tool for vaccine research and evaluation.
Our pre-clinical evaluation platform for cancer vaccines offers strong support and tools for your research. Should you have any questions or require further insights, please don't hesitate to contact us.

Related platforms:
•    Tumor vaccine detection platform for immune-competent mice
    ✓    Various immunization methods
             •    im
             •    sc
             •    ip
             •    iv
             •    Instilled through the airway,
             •    transnasal
•    PBMC immune system humanized mouse tumor vaccine detection platform
    ✓    Establishing an immune system for effective antigen presentation 
•    Tumor vaccine supporting testing platform
    ✓    Medicinal efficacy
             •    In vivo ( CDX , PDX )
             •    In vitro (tumor / immune cell co-culture killing)
    ✓    ELISpot
            •    in vitro antigen presentation
            •    CTL quantity detection
    ✓    Cytokine detection
            •    Luminex , ELISA , flow cytometry
    ✓    Flow detection platform
            •    Immune cell typing analysis
            •    Tetramer method to detect specific CTL
    ✓    In vivo imaging
            •    Transfection efficiency and distribution detection
•    MHC molecule humanized mouse vaccine detection platform.
    ✓    Tap/MHC humanized immune-competent mice

Addressable research needs

•    Tumor Vaccine Evaluation
    ✓    Screen vaccine sequences
    ✓    Screening adjuvants
    ✓    Screen different antigenic peptide sequences
•    Tumor vaccine efficacy
    ✓    Specific CTL co-culture killing in vitro
    ✓    In vivo drug efficacy experiments
•    Antigenic peptide sequence screening
    ✓     Humanized MHC mice
•    Multiple vaccine types
    ✓    LNP coated mRNA vaccine
    ✓    protein vaccine
    ✓     Antigenic peptide